From Plant Based Therapy to Plant-Derived Vesicle-Like Nanoparticles for Cancer Treatment: Past, Present and Future

Int J Nanomedicine. 2025 Mar 17:20:3471-3491. doi: 10.2147/IJN.S499893. eCollection 2025.

Abstract

Cancer stands as a formidable malady profoundly impacting human health. Throughout history, plant-based therapies have remained pivotal in the arsenal against cancer, evolving alongside the epochs. Presently, challenges such as the arduous extraction of active components and potential safety concerns impede the progression of plant-based anticancer therapies. The isolation of plant-derived vesicle-like nanoparticles (PDVLNs), a kind of lipid bilayer capsules isolated from plants, has brought plant-based anticancer therapy into a novel realm and has led to decades of research on PDVLNs. Accumulating evidence indicates that PDVLNs can deliver plant-derived active substances to human cells and regulate cellular functions. Regulating immunity, inducing cell cycle arrest, and promoting apoptosis in cancer cells are the most commonly reported mechanisms of PDVLNs in tumor suppression. Low immunogenicity and lack of tumorigenicity make PDVLNs a good platform for drug delivery. The molecules within the PDVLNs are all from source plants, so the selection of source plants is crucial. In recent years, there has been a clear trend that the source plants have changed from vegetables or fruits to medicinal plants. This review highlights the mechanisms of medicinal plant-based cancer therapies to identify candidate source plants. More importantly, the current research on PDVLN-based cancer therapy and the applications of PDVLNs for drug delivery are systematically discussed.

Keywords: anticancer; drug delivery system; plant-based anticancer therapy; plant-derived vesicle-like nanoparticles.

Publication types

  • Review

MeSH terms

  • Animals
  • Antineoplastic Agents, Phytogenic* / administration & dosage
  • Antineoplastic Agents, Phytogenic* / chemistry
  • Antineoplastic Agents, Phytogenic* / therapeutic use
  • Drug Delivery Systems / methods
  • Humans
  • Nanoparticles* / chemistry
  • Neoplasms* / drug therapy
  • Phytotherapy* / methods
  • Plants, Medicinal* / chemistry

Substances

  • Antineoplastic Agents, Phytogenic

Grants and funding

This work was supported by the China Postdoctoral Science Foundation (2023M741278), Key R & D Program of Hubei Province (2023BCB149), Tongji Hospital Medical Innovation and Transformation Incubation Project (2022ZHFY02), and the National Natural Science Foundation of China (NSFC, 82370770).